LOS ANGELES, CALIFORNIA--(Marketwire - May 7, 2012) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is awaiting its opportunity to readdress the U.S. Federal Food and Drug Administration's Advisory Committee, as it continues to seek approval for its weight-loss drug Locaserin. The meeting is scheduled for May 10, 2012. This will be the second attempt by Arena to gain the favor of the committee, after it submitted additional results in response to concerns expressed by the FDA, within its previous Complete Response Letter and with respect to the company's previous New Drug Application. The company is currently in a race with Vivus, Inc. and Orexigen Therapeutics, Inc, to bring the first weight-loss drug to market in over a decade.

Legitimate Investor reviews the likelihood of Arena being successful in its application, in a new report which can be accessed at:

[ www.LegitimateInvestor.com ]

Legitimate Investor provides Market Research, Analysis and Opinions focused on equities that are in the forefront of the investing public. Legitimate Investor has not been compensated by any of the above-mentioned companies. We act as an independent research portal and caution that all investment entails inherent risks. Please view the full disclaimer at: [ http://www.legitimateinvestor.com/p/disclaimer.html ]

Publication Contributing Sources

• Market Wire